TIDMBVC
RNS Number : 3230D
BATM Advanced Communications Ld
25 June 2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATION EU 596/2014.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES OF AMERICA, CANADA, JAPAN, NEW ZEALAND, OR ANY OTHER
JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL.
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES
OF AMERICA AND NO SECURITIES HAVE BEEN OR WILL BE REGISTERED UNDER
THE UNITED STATES SECURITIES ACT 1933, AS AMENDED, OR UNDER THE
SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION IN THE UNITED
STATES OF AMERICA.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS
ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE PLACING AND
SUBSCRIPTION ANNOUNCEMENT (AS DEFINED BELOW).
For immediate release
25 June 2019
BATM Advanced Communications Limited
("BATM" or the "Company" or the "Group")
Results of Placing and Subscription
BATM raises US$18 million from existing and new investors
BATM (LSE: BVC), a leading provider of real-time technologies
for networking solutions and medical laboratory systems, is pleased
to announce the successful completion of the Placing and
Subscription (the "Fundraise") announced on 24 June 2019 (the
"Placing and Subscription Announcement") to raise US$18
million.
Shore Capital Stockbrokers Ltd ("Shore Capital") acted as sole
bookrunner in connection with the Placing. Rosario Capital Ltd and
its subsidiaries ("Rosario") acted as the Company's adviser solely
in relation to the Subscription by certain institutional and other
investors based in Israel.
Highlights
-- The Company has raised, in aggregate, gross proceeds of US$18
million at a price of 42.5 pence per New Ordinary Share (the "Issue
Price").
-- Pursuant to the Fundraise, a total of 33,283,254 New Ordinary
Shares will be issued, representing 7.6 per cent. of the Company's
enlarged share capital.
-- The Issue Price represents a discount of 5.6 per cent. to the
mid-market closing price of the Company's Ordinary Shares on the
London Stock Exchange on 24 June 2019, being the last practicable
dealing day prior to the Placing and Subscription Announcement.
-- The net proceeds of the Fundraise are expected to be utilised as follows:
o Networking & Cyber division (approx. 90% of funds
raised):
-- potential acquisition opportunities;
-- acceleration of current network function virtualisation
("NFV") development projects with Arm;
-- new product and use case development for 5G (MEC);
-- completion of development of CyberGuard product for NFV use
cases;
-- accelerating proof-of-concepts and working capital for
existing NFV and cyber products; and
-- marketing and sales initiatives.
o Bio-Medical division (approx. 10% of funds raised):
-- acceleration of current development, deployment and
certifications (including patents) in molecular biology
diagnostics; and
-- acceleration of agri-waste and pharma-waste treatment
installations.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on the premium
segment of the Main Market. It is expected that Admission will
become effective at 8.00 a.m. on 1 July 2019. The New Ordinary
Shares shall rank pari passu with the existing Ordinary Shares in
the Company.
Total Voting Rights
Following Admission of the 33,283,254 New Ordinary Shares, the
Company's issued share capital will consist of 437,129,074 Ordinary
Shares with voting rights and that figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
Dr Zvi Marom, CEO of BATM, said: "We are delighted to have
raised $18 million through the successful completion of this
fundraising. We thank our existing investors for their support and
welcome our new shareholders. This is an exciting time for BATM
with great progress being made across our business units, and
particularly with our NFV activities and molecular diagnostics. We
look forward to utilising these funds to accelerate our growth and
to delivering value for our shareholders."
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Shore Capital Stockbrokers
Mark Percy, Anita Ghanekar, James
Thomas +44 20 7408 4050
Rosario Capital Ltd
Nadav Raban, Tamar Cohen +972 3693 1999
Luther Pendragon
Harry Chathli, Claire Norbury, Joe
Quinlan +44 20 7618 9100
Market Abuse Regulation
This announcement is released by BATM Advanced Communications
Limited and contains inside information for the purposes of the
Market Abuse Regulation (EU) 596/2014 ("MAR") and is disclosed in
accordance with the Company's obligations under Article 17 of MAR.
The person who arranged for the release of this announcement on
behalf of BATM Advanced Communications Limited was Dr Zvi Marom,
Chief Executive Officer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROILIFFDREIEFIA
(END) Dow Jones Newswires
June 25, 2019 03:28 ET (07:28 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Apr 2023 to Apr 2024